Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)

The summary for the Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals
Federal Grant Title: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HG-21-007
Type of Funding: Grant
CFDA Numbers: 93.172
CFDA Descriptions: Information not provided
Current Application Deadline: February 1st, 2023
Original Application Deadline: February 1st, 2023
Posted Date: March 30th, 2021
Creation Date: March 30th, 2021
Archive Date: March 9th, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: January 21st, 2022
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-007.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44)
Near-Term Technology Development for Genome Sequencing - STTR (R41/R42)
Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health
Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)
Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...
Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com